Jasper Therapeutics, Inc. (JSPR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Jasper Therapeutics, Inc. (JSPR) closed at USD 0.50 on 2026-10-14, a change of -78.6 % over the past year, with a market capitalization of USD 17.71M.

Jasper Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Jasper Therapeutics, Inc. key figures

Previous close

USD 0.50 (2026-10-14)

1-year change

-78.6 %

Market cap

USD 17.71M

Enterprise value

n/a

P/E ratio (trailing)

-0.48

P/E ratio (forward)

-0.41

EPS (trailing)

-1.12

EPS (forward)

-1.31

PEG ratio

n/a

Price to book

10.64

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

16.16

Employees

n/a

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Jasper Therapeutics, Inc. and compare it with other stocks.